Seven out of ten markers showed a significantly different IHC expression in at least one of the evaluated cohorts whereas CD3, CD4 and 5-LOX were differentially expressed between GBMs and astrocytomas. This evidence concerns the gene ALOX5 and astrocytoma (excluding glioblastoma).